Special Issue

Homage to Jan Svoboda: Recent Advances in Topics Pioneered by his Prague School

Message from the Guest Editors

Jan Svoboda, a pioneer of retrovirology, brilliant scientist and good friend passed away on March 13 this year. He was a living legend in the fields of retrovirology. tumor viruses, and oncogenes. The scientific community will remember Svoboda not only for his seminal work. Numerous students and peers will surely remember him also for his mentorship, life-long contacts, and influence. This Special Issue intends to commemorate Jan's scientific legacy and point out the recent progress in the topics that he established and pursued during his long and fruitful life in science. We also hope to assemble contributions from people who were influenced by Jan, either as his students or collaborators, and who now work on different topics of virology, oncology, immunology, and cell biology. We accept research articles, reviews, and, potentially, brief communications analysing Jan Svoboda's contribution to the basic concepts in virology. Jiri Hejnar Tomas Ruml

Guest Editors

Dr. Jiri Heinar

Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic

Dr. Tomas Ruml

Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Prague, Czech Republic

Deadline for manuscript submissions

closed (31 October 2018)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/9293

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).